Compare Incyte Corporation (INCY) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Trip.com Group Ltd — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Trip.com Group Ltd trades at $38.9 (market cap $23.75B). The key difference: Incyte Corporation and Trip.com Group Ltd are close in size by market cap, and Trip.com Group Ltd pays a 0.42% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Trip.com Group Ltd for 79 Days on average.
| INCY | TCOM | |
|---|---|---|
Market Cap | $22.85B | $23.75B |
Volume | 1,927,029 | 2,089,737 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $78.96 |
52-Week Low | $83.80 | $37.96 |
Typical Hold Time | 33 Days | 79 Days |
Enterprise Value | $18.35B | $15.91B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
Trip.com (TCOM) trades at $37.96, down 0.34% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $1.07, beating expectations by 22%, with revenue growth of 6% year-over-year. Recent regulatory penalties and algorithm changes create headwinds, but analyst consensus remains strongly bullish with a $56.64 price target representing 49% upside potential from current levels.
The stock presents a compelling value opportunity with attractive valuation multiples (P/E 7.34, EV/EBITDA 3.43) and robust profitability (36.9% net margin). However, regulatory risks from recent antitrust actions and technical weakness require careful monitoring. Institutional sentiment remains positive despite near-term volatility, suggesting potential for recovery as travel demand continues to normalize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
